Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma
NCT ID: NCT00048022
Last Updated: 2017-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2002-10-25
2004-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids
NCT00048009
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
NCT01591044
Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT04643158
A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.
NCT00517816
Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
NCT02528214
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dual Integrin Antagonist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently receiving treatment with a stable dose of inhaled corticosteroids for more than 3 months
* In good health as demonstrated by medical history and physical exam
* Negative urine pregnancy test
* Commitment to use two forms of effective contraception simultaneously throughout the study duration and for 1 month after discontinuing therapy
Exclusion Criteria
* Undergoing allergy shots unless on a stable maintenance dose for 3 months before the start of the study
* History of chronic pulmonary diseases other than asthma
* Treatment of conditions other than asthma with oral corticosteroids within 1 month of the start of the study
* Current tobacco usage
* Smoking history of greater than 10 pack-year history of cigarette smoking (number of packs smoked per day times the number of years smoked)
* History or evidence of drug or alcohol abuse
* Diagnosis or evidence of an infectious illness within one month of Visit 1
* Clinically significant diseases as assessed by the study doctor
* Participation in another clinical study with an experimental drug within one month of start of the study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntington Beach, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Mission Viejo, California, United States
San Diego, California, United States
San Diego, California, United States
San Jose, California, United States
Walnut Creek, California, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Louisville, Colorado, United States
Sarasota, Florida, United States
Tallahassee, Florida, United States
Tamarac, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Normal, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Lenexa, Kansas, United States
Metairie, Louisiana, United States
North Dartmouth, Massachusetts, United States
Ypsilanti, Michigan, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
Forked River, New Jersey, United States
Teaneck, New Jersey, United States
Farmingdale, New York, United States
Rochester, New York, United States
Rockville Centre, New York, United States
Asheville, North Carolina, United States
Canton, Ohio, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Eugene, Oregon, United States
Medford, Oregon, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Upland, Pennsylvania, United States
Providence, Rhode Island, United States
Charleston, South Carolina, United States
Austin, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Sugar Land, Texas, United States
Murray, Utah, United States
South Burlington, Vermont, United States
Abingdon, Virginia, United States
Bellingham, Washington, United States
Kirkland, Washington, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Morgantown, West Virginia, United States
Madison, Wisconsin, United States
Ponce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BA16630
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.